Asperosaponin VI

Asperosaponin VI is a saponin component from Dipsacus asper. Asperosaponin VI induces osteoblast differentiation through the BMP-2/p38 and ERK1/2 signaling pathways. Asperosaponin VI protects against hypoxia-induced cardiomyocyte apoptosis by activating the PI3K/Akt and CREB pathways. Additionally, Asperosaponin VI also has antidepressant and wound-healing-promoting activities^[1][2][3][4]. In Vitro: Asperosaponin VI (0.1 nM-10 μM; 24-48 h) can promote the proliferation of MC3T3-E1 cells and primary rat osteoblasts, increase intracellular ALP activity, upregulate the protein level of BMP-2, and increase the phosphorylation of p38 and ERK1/2 to induce the maturation and differentiation of osteoblasts^[1].
Asperosaponin VI (15-60 μg/mL; 24 h) can inhibit apoptosis and improve cell viability in hypoxia-treated H9C2 cells by reducing intracellular LDH and CK activities, increasing the phosphorylation levels of Akt and CREB, increasing the Bcl-2/Bax ratio, and reducing caspase-3 activity^[2].
Asperosaponin VI (0-160 μg/mL; 0-48 h) promotes angiogenesis of HUVECs by upregulating the HIF-1α/VEGF signaling pathway^[3]. In Vivo: Asperosaponin VI (20 mg/kg; intravenous injection; 3 weeks) can accelerate wound healing and angiogenesis in a full-thickness cutaneous wound model of rats^[3].
Asperosaponin VI (40 mg/kg; intraperitoneal injection; 3 weeks) has antidepressant effects in mice with chronic mild stress^[4].